Paragon Rx Clinical, Inc. Paragon Rx Clinical, Inc. Paragon Rx Clinical, Inc. Paragon Rx Clinical, Inc. Paragon Rx Clinical, Inc.

Current Trials

Description of all our current trials

Irritable Bowel Syndrome with Constipation – IBS-C is characterized by recurrent episodes of abdominal and discomfort with associated alternations in bowel habits. The changed of bowel habits may include discomfort constipation. IBS-C is multi-symptom disease and the goal of therapy is to provide treatment that improves its multiple symptoms. Currently, in clinical practice, treatments are typically focused on the treatment of the individual symptoms of Irritable Bowel Syndrome with Constipation (IBS-C). For example, if a patient has mostly constipation symptoms, the patient is typically prescribed a fiber supplement or laxative. If bloating symptoms are present, patient may be prescribed an antispasmodic or dietary modification.

Are you currently experiencing abdominal pain and constipation due to your Irritable Bowel Syndrome condition? You may qualify if you are:

icon

18-85 years of age

icon

Currently experiencing abdominal pain and constipation due to your Irritable Bowel Syndrome condition

icon

Able and willing to take daily reports on your symptoms throughout the study

icon

Able and willing to participate in the clinical research study for approximately 18 weeks

Eligible participants will receive at no cost:

icon

Investigational Medication

icon

Study related care

icon

Compensation time and travel

Chronic Idiopathic Constipation- the current approaches to the treatment of chronic idiopathic constipation (CIC) are limited and for some patients there are significant setbacks that have not been resolved. It would be beneficial to provide a source of relief for constipation that would permit dosing adjustments to optimize efficacy and safety and that would be pleasant to consume to improve patient compliance.

Are you currently experiencing constipation? You may qualify if you are:

icon

You must have had constipation symptoms and fewer than 3 bowel movements per week for at least 12 of the 52 weeks

icon

You must be at least 18 years of age

icon

You must NOT be taking pain medication known to cause constipation

Eligible participants will receive at no cost:

icon

Study-related care and study drug at no cost

icon

Compensation for time and travel

Irritable Bowel Syndrome with Diarrhea (IBS-D)- is a functional bowel disorder in which abdominal pain or discomfort is associated with disordered defecation. The disease may cause discomfort and results in poor quality of life. IBS-D is at least 25% of stools loose or watery and not more than 25% of stools hard or lumpy.

Are you currently experiencing irritable bowel syndrome with diarrhea (IBS-D)? You may qualify if you are:

icon

You must be at least 18 years of age

icon

Recurrent abdominal pain or discomfort for at least 6 months

Eligible participants will receive at no cost:

icon

Study-related care and study drug at no cost

icon

Compensation for time and travel

Colorectal Cancer Screening – Colorectal cancer (CRC) is the second leading cause of death from cancers affecting both men and women in the US. One in 17 Americans will suffer from CRC during his/her lifetime. Early detection by screening has been shown to reduce CRC mortality. According to recent literature, current guidelines for CRC screening in the average-risk population recommend initiation of screening at age 50, as the incidence of both CRC and pre-malignant lesions increases sharply after this age.

You can be part of a nationwide study to collect data over the course of three years for men and women prescribed a stool DNA test.

icon

This screening test is designed to detect stool DNA markers associated with colorectal cancer.

icon

This multi-center clinical research study is looking for men and women 65 years of age or older who are at average risk for colorectal cancer.

icon

Qualified participants may be eligible for compensation for their time.

Pharmacogenomic Testing- Pharmacogenomics is the study of how genetics affect the drug response variations and being able to apply knowledge to individual patient care through diagnostic tests. Pharmacogenomics holds a promise to improve patients’ response to drugs, reduce adverse events and reduce health care costs. It also promises that one day drugs and medications will be tailor-made to the individual and adapted to their individual genetic makeup.

On the recent years, U.S. Food and Drug Administration (FDA) have recommended pharmacogenomics testing for a variety of medications; often there are variations in enzymes that are not essential to the normal metabolism.

Influenza – influenza causes annual epidemics of the acute respiratory illness. Most people who get influenza will recover in a few days to less than 2 weeks, but others might develop complications as a result of influenza. Some of the common symptoms for flu are fever, body ache, cough, sore throat, nasal symptoms.

Are you currently experiencing flu symptoms? You may qualify if you are:

icon

You are between 18 and 65-year-old

icon

Currently experiencing one or more of respiratory symptoms

icon

Be willing to complete all study visits